Dental Care Clinics in Point Pleasant Boro, NJ Accepting Medicare
8 Dental Care Clinics found. Showing 1 - 8
 Jobella Dental Associates, Llc Dentist Medicare: Not Enrolled in Medicare Practice Location: 1115 Arnold Ave, Point Pleasant Boro, NJ 08742 Phone: 732-899-3363 |
Coastal Dental Group South Llc Dentist Medicare: Not Enrolled in Medicare Practice Location: 2407 Bridge Ave, Point Pleasant Boro, NJ 08742 Phone: 732-714-1030 |
Robert A Wojciak Dmd, Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 842 Arnold Ave, Point Pleasant Boro, NJ 08742 Phone: 732-295-8899 Fax: 732-295-3754 |
Keyport Dental Group Dentist Medicare: Not Enrolled in Medicare Practice Location: 2407 Bridge Ave, Point Pleasant Boro, NJ 08742 Phone: 732-714-1030 Fax: 732-714-1142 |
Peter Fam Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 842 Arnold Ave, Point Pleasant Boro, NJ 08742 Phone: 732-295-8899 |
Point Pleasant Dentistry For Children Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 3824 River Rd, Point Pleasant Boro, NJ 08742 Phone: 732-202-7114 Fax: 732-202-7191 |
Point Pleasant Dentistry For Children Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 3824 River Rd, Point Pleasant Boro, NJ 08742 Phone: 732-202-7114 Fax: 732-202-7191 |
Bozza Dental Group, P.a. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 3824 River Rd, Point Pleasant Boro, NJ 08742 Phone: 732-295-1999 Fax: 732-295-2756 |
News Archive
ICU bloodstream infections have reduced by 80%, research shows
Bloodstream infections acquired in UK Intensive Care Units reduced by 80% between 2007 and 2012, according to research funded by the NIHR Guy's and St Thomas' Biomedical Research Centre.
Shared care model for early follow-up of breast cancer survivors
Survivors of early breast cancer will take part in a new nationwide study trialing a shared care model between cancer specialists and GPs for the follow-up care when they have completed their initial treatment.
Provepharm, DFKC partner to launch Methylthioninium chloride Proveblue in Germany
Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm's drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.
Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients
Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.
› Verified 4 days ago